BLTE BELITE BIO INC

Belite Bio to Participate in the 2025 Maxim Growth Summit

Belite Bio to Participate in the 2025 Maxim Growth Summit

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the Maxim Growth Summit on October 22, 2025.

To schedule a one-on-one meeting with management, please reach out to your Maxim representative.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on , , , and  or visit us at .

Media and Investor Relations Contact:

Jennifer Wu

Julie Fallon



EN
16/10/2025

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in the 2025 Maxim Growth Summit

Belite Bio to Participate in the 2025 Maxim Growth Summit SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the Maxim Growth Summit on October 22, 2025. To schedule a one-on-one meeting with management, please reach out to your Maxim representative. About Belite BioBelite Bio is a clinical-stage drug developmen...

October 16, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces China NMPA Agrees to New Drug Application with Pr...

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Center for Drug Evaluation of China’s National Medical P...

October 15, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of ...

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast subject visit completed in the pivotal Phase 3 DRAGON trial of Tinlarebant in Stargardt diseaseTopline data expected in Q4 2025 SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-sta...

September 12, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Up to $275 Million Upsized Private Placement Fina...

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional $150 million tied to exercise of warrantsWarrants exercisable at a 20% premium to purchase price SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("Belite Bio" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advanci...

September 8, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details of the presentations are as follows: Cantor Global Healthcare Conference September 5, 2025, at 8:00 am ET, fireside chat Morgan Stanley 23rd Annual Global Healthc...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch